<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04934124</url>
  </required_header>
  <id_info>
    <org_study_id>ITI-333-001</org_study_id>
    <secondary_id>1UG3DA047699-01</secondary_id>
    <nct_id>NCT04934124</nct_id>
  </id_info>
  <brief_title>Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ITI 333 in Healthy Volunteers</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ITI 333 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intra-Cellular Therapies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Intra-Cellular Therapies, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will be conducted as a single-center, randomized, double-blind, placebo-controlled,&#xD;
      ascending dose study in up to 8 sequential cohorts of healthy subjects. Each cohort will&#xD;
      enroll 8 subjects: 6 subjects will receive ITI-333 and 2 subjects will receive placebo as a&#xD;
      single oral dose after a fast of at least 10 hours.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 26, 2021</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Sequential ascending doses. Parallel (active, placebo) within each cohort</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of subjects with treatment-emergent adverse events</measure>
    <time_frame>up to 30 days after last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in systolic and diastolic blood pressure</measure>
    <time_frame>Up to Day 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in SAO2</measure>
    <time_frame>Up to Day 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in ECG QT interval</measure>
    <time_frame>Up to Day 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in hemoglobin</measure>
    <time_frame>Up to Day 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in white blood cell count</measure>
    <time_frame>Up to Day 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in aspartate aminotransferase</measure>
    <time_frame>Up to Day 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in alanine aminotransferase</measure>
    <time_frame>Up to Day 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: AUC0-t</measure>
    <time_frame>predose and multiple timepoints up to 48 hours postdose</time_frame>
    <description>Area under the plasma concentration time curve from time zero to the last measurable of concentration of ITI-333 and potential metabolites</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: AUC0-inf</measure>
    <time_frame>predose and multiple timepoints up to 48 hours postdose</time_frame>
    <description>Area under the plasma concentration (ITI-333 and potential metabolites) time curve from time zero to infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Cmax</measure>
    <time_frame>predose and multiple timepoints up to 48 hours postdose</time_frame>
    <description>Maximum plasma concentration of ITI-333 and potential metabolites</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Tmax</measure>
    <time_frame>predose and multiple timepoints up to 48 hours postdose</time_frame>
    <description>Time of maximum concentration of ITI-333 and potential metabolites in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: T1/2</measure>
    <time_frame>predose and multiple timepoints up to 48 hours postdose</time_frame>
    <description>Terminal elimination half-life of ITI-333 and potential metabolites</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: CL/F</measure>
    <time_frame>predose and multiple timepoints up to 48 hours postdose</time_frame>
    <description>Apparent oral clearance of ITI-333</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Vz/F</measure>
    <time_frame>predose and multiple timepoints up to 48 hours postdose</time_frame>
    <description>Apparent volume of distribution of ITI-333</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Cohort 1: 0.03 mg ITI-333 or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: 0.09 mg ITI-333 or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: 0.25 mg ITI-333 or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: 0.75 mg ITI-333 or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5: 2.25 mg ITI-333 or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6: 6.75 mg ITI-333 or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 7: 15 mg ITI-333 or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 8: 30 mg ITI-333 or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ITI-333</intervention_name>
    <description>ITI-333 oral solution</description>
    <arm_group_label>Cohort 1: 0.03 mg ITI-333 or placebo</arm_group_label>
    <arm_group_label>Cohort 2: 0.09 mg ITI-333 or placebo</arm_group_label>
    <arm_group_label>Cohort 3: 0.25 mg ITI-333 or placebo</arm_group_label>
    <arm_group_label>Cohort 4: 0.75 mg ITI-333 or placebo</arm_group_label>
    <arm_group_label>Cohort 5: 2.25 mg ITI-333 or placebo</arm_group_label>
    <arm_group_label>Cohort 6: 6.75 mg ITI-333 or placebo</arm_group_label>
    <arm_group_label>Cohort 7: 15 mg ITI-333 or placebo</arm_group_label>
    <arm_group_label>Cohort 8: 30 mg ITI-333 or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo</description>
    <arm_group_label>Cohort 1: 0.03 mg ITI-333 or placebo</arm_group_label>
    <arm_group_label>Cohort 2: 0.09 mg ITI-333 or placebo</arm_group_label>
    <arm_group_label>Cohort 3: 0.25 mg ITI-333 or placebo</arm_group_label>
    <arm_group_label>Cohort 4: 0.75 mg ITI-333 or placebo</arm_group_label>
    <arm_group_label>Cohort 5: 2.25 mg ITI-333 or placebo</arm_group_label>
    <arm_group_label>Cohort 6: 6.75 mg ITI-333 or placebo</arm_group_label>
    <arm_group_label>Cohort 7: 15 mg ITI-333 or placebo</arm_group_label>
    <arm_group_label>Cohort 8: 30 mg ITI-333 or placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male and female subjects between 18 and 45 years old (inclusive);&#xD;
&#xD;
          -  BMI inclusive of 18-32 kg/m2 at screening and a minimum weight of 50 kg;&#xD;
&#xD;
          -  Willingness to remain in the clinic for the inpatient portion of the study and return&#xD;
             for follow-up visit(s) as required by protocol and as deemed necessary by the&#xD;
             Investigator;&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Clinically significant abnormality within 2 years of Screening that in the&#xD;
             Investigator's opinion may place the subject at risk or interfere with study outcome&#xD;
             variables; this includes, but is not limited to, history of or current cardiac,&#xD;
             hepatic, renal, neurologic, GI, pulmonary, endocrinologic, hematologic, or immunologic&#xD;
             disease or history of malignancy;&#xD;
&#xD;
          -  Clinically significant abnormal findings in vital sign assessments, including blood&#xD;
             oxygen saturation (SAO2) &lt; 96% and &lt; 12 breaths per min; History of psychiatric&#xD;
             condition that in the Investigator's opinion may be detrimental to participation in&#xD;
             the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>ITI Clinical Trials</last_name>
    <phone>646 440-9333</phone>
    <email>ITCIClinicalTrials@itci-inc.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Eatontown</city>
        <state>New Jersey</state>
        <zip>07724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>June 14, 2021</study_first_submitted>
  <study_first_submitted_qc>June 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 22, 2021</study_first_posted>
  <last_update_submitted>June 14, 2021</last_update_submitted>
  <last_update_submitted_qc>June 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

